In vivo anti-tumor activity of the PARP inhibitor niraparib in homologous recombination deficient and proficient ovarian carcinoma(,)

OBJECTIVE: Poly(ADP-ribose) polymerase (PARP) inhibitors have yielded encouraging responses in high-grade serous ovarian carcinomas (HGSOCs), but the optimal treatment setting remains unknown. We assessed the effect of niraparib on HGSOC patient-derived xenograft (PDX) models as well as the relation...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Gynecol Oncol
Main Authors: AlHilli, Mariam M., Becker, Marc A., Weroha, S. John, Flatten, Karen S., Hurley, Rachel M., Harrell, Maria I., Oberg, Ann L., Maurer, Matt J., Hawthorne, Kieran M., Hou, Xiaonan, Harrington, Sean C., McKinstry, Sarah, Meng, X. Wei, Wilcoxen, Keith M., Kalli, Kimberly R., Swisher, Elizabeth M., Kaufmann, Scott H., Haluska, Paul
Formato: Artigo
Idioma:Inglês
Publicado em: 2016
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5370566/
https://ncbi.nlm.nih.gov/pubmed/27614696
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ygyno.2016.08.328
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados